PRODUCTS
Tongxinluo Capsules
Shensong Yangxin Capsules
Qili Qiangxin Capsule
Lianhua Qingwen Capsules

  • Drug name: Qili Qiangxin Capsule
  • Approval No.: GYZZ Z20040063
  • Specification: 0.3g/capsule.
  • Dosage: Take orally, 4 capsules/time, 3 times/day.
  • Shelf-life: 30 months
  • Ingredients: Astragali Radix, Ginseng Radix et Rhizoma, Aconiti Lateralis Radix Preparata, Salvia miltiorrhiza Radix et Rhizoma, Descurainiae Semen lepidii Semen, Alismatis Rhizoma, Polygonati Odorati Rhizoma, Cinnamomi Ramulus, Carthami Flos, Periplocae Cortex, Citri Reticulatae Pericarpium.
  • Functions and Indications: Tonify qi and warm Yang, activate blood and unblock collaterals, induce diuresis to alleviate edema, it is used for mild and moderate congestive heart failure caused by coronary heart disease and hypertension, indicated by yang deficiency, blood blocking and liquid stagnation; with the symptoms as flusteredness and short breath, more seriously when moving; unable to lie on back during sleep; legs edema; tireness and asthenia; less urine; mouth and lips hematocyanosis; chilly and cold in limbs, spit watery white phlegm.

Qili Qiangxin Capsules, a New Patent Drug for Chronic Heart Failure Resolving both Symptoms and Root Causes


Heart failure is a kind of ultimate death resulting disease at the late stages of the various kinds of heart diseases. Significant breakthroughs in this area are rare during the last several decades. The research and development of effective products for the treatment of heart failure is still an important topic in the international medical field. The broad comparisons made between the Qili Qiangxin Capsules developed as guided by the collateral disease theory and the western medicines show that it has the synergy effects of four kinds of tier one and tier two western products. It can also better effects in reducing myocardial apoptosis and improving energy metabolism, which allows it an outstanding advantage.

  • Its cardiotonic effect is equivalent to that of the digitalis western medicines (Digoxin)

  • It can reduce the myocardial apoptosis and autophagy

  • It has better effect in reducing renal aquaporin 2 than that of the western medicine Furosemide.

  • It can promote the proliferation of the myocardial cells.

  • It has better Angll inhibition effect than that of the western medicine Ramipril.

  • It can improve the energy metabolism of the cardiac muscles.

  • It has better effect in ventricular remodeling inhibition that that of the western medicine Metoprolol.

  • It can be used for the treatment of arrhythmia

  • A Model High-tech Industrialization Project of National Development and Reform Commission

  • An Innovative TCM Patent Drug for Chronic Heart Failure Resolving both Symptoms and Root Causes as Proved by Clinical Evidence Based Medicine

  • An Innovative TCM Patent Drug for Chronic Heart Failure with Excellent Therapeutic Effects Recognized by International Authoritative Journals

  • Recognized as a Recommended Innovative TCM Patent Drug by Heart Failure Diagnosis and Treatment Guide of Chinese Medical Association

  • Listed in the List of National Essential Drugs

  • A Product in the National Health Insurance Program

  • A High-tech Product of the Ministry of Science and Technology

  • A National Level Key New Product

  • A Project Funded by the National 863 Program of the Ministry of Science and Technology

  • A Backbone Science and Technology Project in the "Eleventh Five-year Plan"

Guideline/Standard Therapy/Clinical Route

  • 《Chinese Guide on Diagnosis and Treatment of Heart Failure (2018)》
  • 《Chinese Guide on Diagnosis and Treatment of Dilated Cardiomyopathy》

Textbooks

Integrated Chinese and Western Internal Medicine (Edition III, New Century)

Expert Consensus Documents

《Expert Consensus Document on Diagnosis and Treatment of Heart Failure through Integrated Chinese and Western Medicine》

Heart failure is a kind of ultimate death resulting disease at the late stages of the various kinds of heart diseases. Significant breakthroughs in this area are rare during the last several decades. The research and development of effective products for the treatment of heart failure is still an important topic in the international medical field. The broad comparisons made between the Qili Qiangxin Capsules developed as guided by the collateral disease theory and the western medicines show that it has the synergy effects of four kinds of tier one and tier two western products. It can also better effects in reducing myocardial apoptosis and improving energy metabolism, which allows it an outstanding advantage.

  • Its cardiotonic effect is equivalent to that of the digitalis western medicines (Digoxin).
  • It has better effect in reducing renal aquaporin 2 than that of the western medicine Furosemide.
  • It has better Angll inhibition effect than that of the western medicine Ramipril.
  • It has better effect in ventricular remodeling inhibition that that of the western medicine Metoprolol.
  • It can reduce the myocardial apoptosis and autophagy.
  • It can promote the proliferation of the myocardial cells.
  • It can improve the energy metabolism of the cardiac muscles.
  • It can be used for the treatment of arrhythmia
Chief Researchers: Academician Gao Runlin, Academician Zhang Boli, Professor Huang Jun, Professor Li Xinli, and Professor Zhang Jian
Study Organizations: 23 Tier Three Class A hospitals led by the No. 1 Affiliated Hospital of Nanjing Medical University and Fuwai Hospital of Chinese Academy of Medical Sciences
  • The serum level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is significantly reduced. The reduction is more than 30%, which is far higher than that of the control product.
  • The Minnesota Living with Heart Failure Questionnaire score is reduced.
  • The cardiac function is improved and the left ventricular ejection fraction is increased.
  • The 6min walking distance is increased for the heart failure patients.
  • The incidence of composite outcomes events is reduced.
 

   Read this leaflet carefully, and take this medicine under the doctor or  pharmacists’ direction

  The product containing Prepared Common Monkshood Daughter Root

  [Drug name]

  Generic name: Qili Qiangxin Capsules

  ChinesePin yin: Qili Qiangxin Jiaonang

  [Ingredients]Milkvetch Root,Ginseng, Prepared Common Monkshood Daughter  Root,Danshen Root,Tansymustard Seed,Oriental Waterplantain Rhizome, Fragrant  Solomonseal Rhizome, Cassia Twig,Safflower, Chinese Silkvine Root-bark, Dried  Tangerine Peel

  [Description] Capsules containing sepia to brown granules; taste  bitter.

  [Functions and Indications]Tonifyqi and warmYang,activate blood and unblock  collaterals, induce diuresis to alleviate edema, it is used for mild and  moderate congestive heart failure caused by coronary heart disease and  hypertension, indicated by yang deficiency, blood blocking and liquid  stagnation; withthe symptomsas flusteredness and short breath, more seriously  when moving; unable to lie on back during sleep; legs edema; tireness and  asthenia; less urine; mouth and lips hematocyanosis; chilly and cold in limbs,   spit watery white phlegm.

  [Strength]0.3g/capsule

  [Administration and Dosage]For oral administration, 4 capsules once, 3  times daily.

  [Adverse Reactions]Unclear

  [Contraindictions]Unclear

  [Precautions]Ifother heart failure drugs are used simultaneously, it is not  recommended to stop the drug in a sudden.Please protect from moisture after  opening the moisture proof bag.

  [Pharmacology and Toxicology]Pharmacodynamic experiments show that: for  experimental heart failure model of dog caused by pentobarbital and experimental  chronic heart failuremodel of rabbit caused by aorta abdominalis ligation, this  medicine could increase the myocardial contractility, cardiac output, kidney  blood flow volume, decrease ventricle wall thickness, cardiac index, level of angiotensinⅡ and aldosterone, alleviate ventricle reconstruction. This medicine  also could increase the amount ofmicturition in rat, and prolong life span of  mouse under normal atmosphere, and extend mouse swimming time underlow  temperature.

  [Storage]Preserve in tightly closed containers.

  [Package]Aluminium-plastic package,36 capsules/box

  [Shelf-life]30 months

  [Executive standard]Chinese Pharmacopoeia 2010, the 2nd supplemental  volume

  [Approval No.]GYZZ Z20040141

  [Manufacturer]

  Company name: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

  Manufacture address:No.238 Tianshan street, New and high development area,  Shijiazhuang, Hebei, China.

  Post code: 050035

  Tel:800 8038581, +8631185901719, 400 8165108

  Fax:+8631185901719

  Registration address:No.238 Tianshan street, New and high development area,  Shijiazhuang, Hebei, China.

  Website: http://www.yiling.cn

  SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD